ClinicalTrials.gov
ClinicalTrials.gov Menu

Prospective, Randomized, Open Label, Phase II Study to Assess Efficacy and Safety of Macugen® (Pegaptanib 0.3 mg Intravitreal Injections) Plus Panretinal Photocoagulation and PRP (Monotherapy) in the Treatment With High Risk PDR.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01281098
Recruitment Status : Completed
First Posted : January 21, 2011
Last Update Posted : March 19, 2015
Sponsor:
Information provided by (Responsible Party):
Association for Innovation and Biomedical Research on Light and Image

No Study Results Posted on ClinicalTrials.gov for this Study
  Recruitment Status : Completed
  Actual Primary Completion Date : October 2012
  Actual Study Completion Date : February 2013